- Earnings per Share (EPS) reported at -$0.09, missing the estimated EPS.
- Revenue exceeded expectations, reaching $35.41 million, an 18% increase year-over-year.
- Raised revenue guidance for fiscal year 2025 to $131 to $135 million, indicating an anticipated growth of 11% to 15%.
Xtant Medical Holdings, Inc. (AMEX:XTNT) is a global medical technology company that specializes in the development and commercialization of regenerative medicine products and medical devices. The company focuses on providing solutions for orthopedic and neurological applications. In a competitive landscape, XTNT strives to differentiate itself through its core biologics business, as emphasized by its President and CEO, Sean Browne.
On August 12, 2025, XTNT reported its earnings, revealing an earnings per share (EPS) of -$0.09, which was significantly lower than the estimated EPS of -$0.01. Despite this, the company exceeded revenue expectations, generating $35.41 million compared to the estimated $31.2 million. This revenue marks an 18% increase compared to the previous year, showcasing the company’s ability to grow its top line effectively.
XTNT’s financial performance in Q2 2025 was further discussed during its earnings conference call, where CFO Scott C. Neils provided insights into the company’s strategic direction. The company has raised its revenue guidance for the fiscal year 2025 to a range of $131 to $135 million, representing an anticipated growth of 11% to 15% over the fiscal year 2024. This optimistic outlook reflects XTNT’s confidence in its business strategy and market position.
Despite a negative price-to-earnings (P/E) ratio of -7.95, XTNT’s price-to-sales ratio of 0.76 suggests that the company’s stock is valued at less than one times its sales. This indicates potential undervaluation in the market. The enterprise value to sales ratio is approximately 1, showing a close alignment between the company’s enterprise value and its sales, which can be a positive sign for investors.
XTNT’s financial metrics also reveal a moderate debt-to-equity ratio of 0.78, indicating a balanced approach to leveraging debt. The current ratio of 2.34 suggests a strong liquidity position, with more than twice the current assets compared to its current liabilities. This financial stability, combined with the company’s strategic focus on its core biologics business, positions XTNT for potential future growth and profitability.
